Eli Lilly arthritis drug wins emergency approval for COVID-19 use

Arthritis drug baricitinib is authorised for emergency use in combination remdesivir to treat COVID-19 patients.

Eli Lilly logo
In a clinical trial of hospitalised patients with COVID-19, baricitinib along with remdesivir was shown to reduce time to recovery to within 29 days after starting treatment [File: Daniel Acker/Bloomberg]

The United States Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co’s arthritis drug, baricitinib, in combination with Gilead Sciences Inc’s remdesivir, to treat COVID-19 patients.

Baricitinib, sold under the brand name of Olumiant, is an FDA-approved oral medication to treat moderately-to-severely active rheumatoid arthritis.

The approval was based on a review of the data from a clinical trial of hospitalised COVID-19 patients sponsored by the National Institute of Allergy and Infectious Diseases.

The trial showed an approximately one-day reduction in median recovery time for patients treated with the combination versus those treated with remdesivir.

The health regulator approved the drug in combination with remdesivir for treating suspected or laboratory-confirmed COVID-19 in hospitalised adults and children two years of age or older requiring oxygen support.

Source: Reuters


More from Economy
Most Read